LCM
CRL icon

LRT Capital Management’s Charles River Laboratories CRL Stock Holding History

LRT Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.35M Buy
+23,585
New +$4.2M 3.47% 7
2025
Q1 		– Sell
-10,832
Closed -$2M – 89
2024
Q4 		$2M Buy
+10,832
New +$2.09M 1.56% 22

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

LRT Capital Management's CRL Position: Q2 2026 in Review

LRT Capital Management opened a new position in Charles River Laboratories (CRL) in Q2 2026: 23,585 shares worth $5.35M. The stake represents 3.47% of the portfolio and ranks #7 among its holdings. This is a return to the name: LRT Capital Management previously reported a position in CRL as recently as Q4 2024.

LRT Capital Management first reported a position in CRL in Q4 2024 and has held it in 2 quarters since. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • LRT Capital Management held 23,585 shares of Charles River Laboratories worth $5.35M as of Q2 2026.
  • Charles River Laboratories was a new LRT Capital Management position in Q2 2026.
  • Charles River Laboratories made up 3.47% of LRT Capital Management's portfolio in Q2 2026, its #7 holding.
  • LRT Capital Management first reported a position in Charles River Laboratories in Q4 2024 and has held it in 2 quarters since.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on LRT Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.